{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 0, "question": "How many clients does 2U, Inc. have as of December 31, 2023?", "prediction": "According to the filing, 2U, Inc. has more than 260 clients with more than 4,500 offerings as of December 31, 2023.", "ground_truth": "2U, Inc. has more than 260 clients as of December 31, 2023."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 1, "question": "As of December 31, 2023, how many executive-sponsored business resource networks (BRNs) did the company have?", "prediction": "According to the document, as of December 31, 2023, the company had 9 BRNs focused on Black/African Americans, Women, LGBTQ+, Asian & Pacific Islanders, Latinx, Persons with disabilities, Jewish employees, Black African employees (in South Africa) and Parents and Caregivers.", "ground_truth": "The company had 9 executive-sponsored business resource networks."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 2, "question": "What was the net carrying value of the edX trade name as of December 31, 2023?", "prediction": "As of December 31, 2023, the net carrying value of the edX trade name was $76.7 million.", "ground_truth": "$76.7 million."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 3, "question": "What is the required minimum Recurring Revenues as per the Second Amended Credit Agreement?", "prediction": "According to the document, the Second Amended Credit Agreement requires the Company to maintain $900 million minimum Recurring Revenues (as defined by the Second Amended Credit Agreement) as of the last day of any period of four consecutive fiscal quarters.", "ground_truth": "$900 million."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 4, "question": "What is the term expiration year for the lease of 2U, Inc.'s headquarters in Lanham, Maryland?", "prediction": "According to the document, 2U's headquarters lease in Lanham, Maryland expires in 2028.", "ground_truth": "2028."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 6, "question": "What was the translation adjustment loss for foreign currency for the year ended December 31, 2023?", "prediction": "According to the consolidated statements of operations and comprehensive loss, the foreign currency translation adjustment loss was $5,671,000 for the year ended December 31, 2023.", "ground_truth": "The foreign currency translation adjustment loss was $5.7 million."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 7, "question": "What kind of liabilities does the Company recognize related to uncertain tax positions?", "prediction": "According to Note 2 of the financial statements, as of December 31, 2023 and 2022, the Company has not recognized any amounts for uncertain tax positions.", "ground_truth": "The Company records a liability for unrecognized tax benefits resulting from uncertain tax positions."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 8, "question": "What is the total future minimum payment that 2U, Inc. is obligated to make to university clients as of December 31, 2023?", "prediction": "According to the financial statements, 2U, Inc.'s total future minimum payments due to university clients as of December 31, 2023 is $17,569,000.", "ground_truth": "$17,569,000."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 9, "question": "How much stock-based compensation expense was recognized in 2022?", "prediction": "According to the consolidated financial statements, 2U, Inc. recognized $80,220,000 in total stock-based compensation expense for the year ended December 31, 2022.", "ground_truth": "$80.2 million."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 0, "question": "What is the name of the wholly-owned biotech company formed by 3D Systems in 2022?", "prediction": "According to the financial statements, 3D Systems formed Systemic Bio in 2022 as a wholly-owned biotech company to accelerate progress in developing 3D-printed vascularized \"organs-on-chips\" for pharmaceutical industry customers.", "ground_truth": "Systemic Bio."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 1, "question": "Who is the company's Executive Vice President and Chief Technology Officer for Regenerative Medicine?", "prediction": "According to the filing, Charles W. Hull is the Executive Vice President and Chief Technology Officer for Regenerative Medicine. He is a founder of the company and previously served on the Board of Directors from 1993 to May 2022.", "ground_truth": "Charles W. Hull."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 2, "question": "How many shares of the company's common stock were surrendered for tax withholding obligations in December 2022?", "prediction": "According to the table in Item 5, 67,575 shares of common stock were surrendered for tax withholding obligations in December 2022.", "ground_truth": "67,575 shares of common stock were surrendered for tax withholding obligations in December 2022."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 3, "question": "What was the total revenue for the year ended December 31, 2022?", "prediction": "The total revenue for the year ended December 31, 2022 was $538,031,000.", "ground_truth": "$538.0 million."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 4, "question": "What percentage of 3D Systems' net sales in 2022 was attributable to entities with functional currencies other than the U.S. dollar?", "prediction": "According to the financial statements, in 2022 approximately 39.4% of 3D Systems' net sales was attributable to entities with functional currencies other than the U.S. dollar.", "ground_truth": "Approximately 39.4% of net sales."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 5, "question": "What was the net loss income attributable to 3D Systems Corporation for the year ended December 31, 2022?", "prediction": "The net loss attributable to 3D Systems Corporation for the year ended December 31, 2022 was $122,711,000.", "ground_truth": "$(122,711)"}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 6, "question": "What was the net income attributable to 3D Systems Corp. for the year ended December 31, 2021?", "prediction": "According to the Consolidated Statements of Operations, the net income attributable to 3D Systems Corporation for the year ended December 31, 2021 was $322,052,000.", "ground_truth": "$322,052."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 7, "question": "What was the fair value of cash acquired with the Volumetric acquisition?", "prediction": "According to Note 3 of the financial statements, the cash acquired with the Volumetric acquisition was $389,000.", "ground_truth": "$389."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 8, "question": "What was the total revenue for 3D Systems Corporation for the year ended December 31, 2022?", "prediction": "According to the Consolidated Statements of Operations, 3D Systems Corporation's total revenue for the year ended December 31, 2022 was $538,031,000.", "ground_truth": "$538,031,000."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 9, "question": "How many shares of restricted stock that vest under specified Company performance measures were included in the outstanding balance as of December 31, 2022?", "prediction": "According to the financial statements, 1,215 shares of restricted stock that vest under specified Company performance measures were included in the outstanding balance as of December 31, 2022.", "ground_truth": "1,215 shares of restricted stock."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 0, "question": "What date did Square, Inc. change its corporate name to Block, Inc.?", "prediction": "According to the filing, Square, Inc. changed its corporate name to Block, Inc. on December 1, 2021.", "ground_truth": "On December 1, 2021, Square, Inc. changed its corporate name to Block, Inc."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 1, "question": "As of December 31, 2023, how many full-time employees did the company have worldwide?", "prediction": "According to the report, as of December 31, 2023, Block had 12,985 full-time employees worldwide, with 3,154 full-time employees outside the US.", "ground_truth": "The company had 12,985 full-time employees worldwide."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 2, "question": "What portion of Bitcoin does the company hold in offline and air-gapped cold storage?", "prediction": "According to the document, the vast majority (\"materially all\") of bitcoin held for other parties is stored in secure cold storage that is offline and air-gapped. This is mentioned on page 83 of the filing in the context of how the company mitigates risk of loss for bitcoin held on behalf of customers.", "ground_truth": "The vast majority of bitcoin we hold for ourselves and our customers is held in offline and air-gapped cold storage."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 3, "question": "As of December 31, 2023, what was the outstanding aggregate principal amount of 2025 Convertible Notes?", "prediction": "As of December 31, 2023, the outstanding aggregate principal amount of 2025 Convertible Notes was $1.0 billion.", "ground_truth": "$1.0 billion."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 4, "question": "As of February 16, 2024, how many holders of record were there for Block, Inc.'s Class A common stock?", "prediction": "According to the document, as of February 16, 2024, Block, Inc. had 637 holders of record of its Class A common stock.", "ground_truth": "As of February 16, 2024, there were 637 holders of record for Block, Inc.'s Class A common stock."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 5, "question": "What was the increase in net cash provided by investing activities for the year ended December 31, 2023?", "prediction": "According to the consolidated statements of cash flows, net cash provided by investing activities was $683,201,000 for the year ended December 31, 2023, compared to $1,225,696,000 for 2022. This actually represents a decrease of $542,495,000 in net cash provided by investing activities, not an increase.", "ground_truth": "Net cash provided by investing activities increased by $683.2 million."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 6, "question": "What was Block, Inc.'s total revenue for the year ended December 31, 2023?", "prediction": "Block, Inc.'s total revenue for the year ended December 31, 2023 was $21,915,623,000 ($21.9 billion).", "ground_truth": "$21,915,623,000."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 7, "question": "What was the total net revenue for the year ended December 31, 2023?", "prediction": "The total net revenue for the year ended December 31, 2023 was $21,915,623,000.", "ground_truth": "$21,915,623,000."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 8, "question": "What was the credit provision for consumer receivables acquired from Afterpay from January 31, 2022, to December 31, 2022?", "prediction": "According to Note 6 in the financial statements, the provision for credit losses for consumer receivables acquired from Afterpay was $203.7 million from the acquisition date of January 31, 2022 to December 31, 2022.", "ground_truth": "$203,670,000."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 9, "question": "What was the total amount of shares repurchased by the Company during the year ended December 31, 2023?", "prediction": "During the year ended December 31, 2023, the Company repurchased 2,466,000 shares of its Class A common stock for $156.8 million.", "ground_truth": "2.5 million shares of Class A common stock."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 0, "question": "What was C.H. Robinson Worldwide, Inc.'s total consolidated revenue for the year ended December 31, 2023?", "prediction": "C.H. Robinson Worldwide, Inc.'s total consolidated revenue for the year ended December 31, 2023 was $17.6 billion.", "ground_truth": "C.H. Robinson Worldwide, Inc.'s total consolidated revenue was $17.6 billion in 2023."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 1, "question": "What was the engagement score from the 2023 survey?", "prediction": "According to the document, C.H. Robinson's 2023 engagement survey generated an engagement score of 77%.", "ground_truth": "77 percent."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 2, "question": "When did Michael P. Zechmeister plan to retire from his position as Chief Financial Officer?", "prediction": "According to the filing, Michael P. Zechmeister will depart his position as Chief Financial Officer upon the appointment of his successor or no later than May 31, 2024, at which time he plans to retire.", "ground_truth": "No later than May 31, 2024."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 3, "question": "Where is the corporate headquarters of C.H. Robinson Worldwide, Inc. located?", "prediction": "C.H. Robinson's corporate headquarters is located in Eden Prairie, Minnesota.", "ground_truth": "The corporate headquarters is in Eden Prairie, Minnesota."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 4, "question": "What was the diluted net income per share for the twelve months ended December 31, 2023?", "prediction": "The diluted net income per share for the twelve months ended December 31, 2023 was $2.72.", "ground_truth": "$2.72."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 5, "question": "What was the effect of exchange rates on cash and cash equivalents for the year ended December 31, 2023?", "prediction": "According to the Consolidated Statements of Cash Flows, the effect of exchange rates on cash and cash equivalents was a decrease of $3,284,000 for the year ended December 31, 2023.", "ground_truth": "A decrease of $3,284,000."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 6, "question": "What was the opinion expressed by the auditing firm regarding C.H. Robinson Worldwide, Inc.'s internal control over financial reporting as of December 31, 2023?", "prediction": "According to Deloitte & Touche LLP's report, they expressed an unqualified opinion that C.H. Robinson Worldwide, Inc. maintained effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO.", "ground_truth": "The auditing firm expressed that C.H. Robinson Worldwide, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 7, "question": "What was the carrying value of total debt as of December 31, 2023?", "prediction": "The carrying value of total debt was $1,580,487,000 as of December 31, 2023.", "ground_truth": "$1,580,487 thousand."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 8, "question": "What was the total value of shares repurchased by the company in 2023?", "prediction": "According to the financial statements, C.H. Robinson repurchased shares valued at $62.8 million in 2023.", "ground_truth": "$62,778 thousand."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 9, "question": "What was the amount of total restructuring charges recognized for the 2023 South American Restructuring Program?", "prediction": "According to Note 15 of the financial statements, C.H. Robinson recognized $21.2 million in net restructuring charges related to their South American Restructuring Program in 2023.", "ground_truth": "$21.2 million."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 0, "question": "What was the total revenue for Exact Sciences Corporation for the year ended December 31, 2023?", "prediction": "The total revenue for Exact Sciences Corporation for the year ended December 31, 2023 was $2,499.8 million.", "ground_truth": "$2.50 billion."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 1, "question": "As of December 31, 2023, how many issued patents does the company own in the U.S.?", "prediction": "According to the document, as of December 31, 2023, the company had 208 issued patents in the U.S.", "ground_truth": "As of December 31, 2023, the company owns 208 issued patents in the U.S."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 2, "question": "What location houses both the headquarters and one of the test facilities?", "prediction": "According to the notes, Madison, Wisconsin houses both the Company's headquarters and clinical laboratory operations facilities.", "ground_truth": "Madison, Wisconsin houses both the headquarters and one of the test facilities."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 3, "question": "What was the settlement amount paid by the company in September 2023 due to a civil investigative demand related to Genomic Health's Medicare billing compliance?", "prediction": "According to the financial statements, the company paid $32.5 million in September 2023 to settle the civil investigation concerning Genomic Health's compliance with the Medicare Date of Service billing regulations.", "ground_truth": "The settlement amount paid in September 2023 was $32.5 million."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 4, "question": "As of December 31, 2023, what is the total indebtedness of the company?", "prediction": "According to the financial statements, as of December 31, 2023, the company had total indebtedness of $2.39 billion, which includes $2.34 billion in aggregate principal and interest due under convertible senior notes and $50.0 million in borrowings under their Securitization Facility.", "ground_truth": "The total indebtedness is $2.39 billion."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 5, "question": "What is the projected fiscal year range for the Thrive milestone payments related to FDA approval and CMS coverage?", "prediction": "According to the notes to the financial statements, the projected fiscal year of payment range for the Thrive milestone payments (FDA approval and CMS coverage) is from 2028 to 2030.", "ground_truth": "The projected fiscal year of payment range is from 2028 to 2030."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 6, "question": "What was the net loss for Exact Sciences Corporation for the year ended December 31, 2023?", "prediction": "Exact Sciences Corporation reported a net loss of $204.1 million for the year ended December 31, 2023.", "ground_truth": "$204,149,000."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 7, "question": "What was the total revenue of EXACT Sciences Corporation for the year ended December 31, 2023?", "prediction": "EXACT Sciences Corporation's total revenue for the year ended December 31, 2023 was $2,499.8 million.", "ground_truth": "$2,499,766,000."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 8, "question": "When will the license agreement with Mayo expire?", "prediction": "According to Note 11 in the financial statements, the license agreement with Mayo will remain in effect until the last licensed patent expires in 2043 (or later, if certain licensed patent applications are issued). However, if the Company is still using Mayo's know-how or biological specimens at that time, the agreement will continue until the earlier of when they stop using such materials or 5 years after the last patent expires.", "ground_truth": "The license agreement will remain in effect until the last of the licensed patents expires in 2039."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 9, "question": "What was the acquisition date fair value of the consideration transferred for the Ashion Acquisition?", "prediction": "According to the financial statement, the acquisition date fair value of the consideration transferred for the Ashion Acquisition was approximately $110.0 million, consisting of $74.8 million in cash, $16.2 million in common stock issued, and $19.0 million in contingent consideration.", "ground_truth": "The acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 0, "question": "What was the total collaboration revenue recognized during the year ended December 31, 2023?", "prediction": "According to the financial statements, the total collaboration revenue recognized during the year ended December 31, 2023 was $38.0 million.", "ground_truth": "$38.0 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 1, "question": "What is the expiration date of U.S. Patent No. 7,335,799 covering bempedoic acid, including patent term adjustment?", "prediction": "According to the document, U.S. Patent No. 7,335,799 covering bempedoic acid is scheduled to expire in December 2025, which includes 711 days of patent term adjustment.", "ground_truth": "December 2025."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 2, "question": "How many full-time employees did the company have as of December 31, 2023?", "prediction": "According to the document, the company had 240 full-time employees as of December 31, 2023.", "ground_truth": "The company had 240 full-time employees as of December 31, 2023."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 3, "question": "Which regulatory authorities have granted approval for the company’s leading product candidates as an adjunct to diet and statin therapy for the treatment of primary hyperlipidemia?", "prediction": "According to the document, the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and Swissmedic (Swiss Agency for Therapeutic Products) have granted approval for both of the company's leading products in 2020.", "ground_truth": "The FDA, the EC, and Swissmedic."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 4, "question": "What is the annual aggregate coverage limit of the product liability insurance for clinical studies?", "prediction": "According to the text, the company maintains product liability insurance coverage for clinical studies with a $10.0 million annual aggregate coverage limit.", "ground_truth": "$10.0 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 5, "question": "What is the senior security interest granted to Oberland under the RIPA?", "prediction": "According to the financial statements, under the Revenue Interest Purchase Agreement (RIPA), Oberland has a senior security interest in certain assets of Esperion, though the specific assets covered by this security interest are not explicitly detailed in the document.", "ground_truth": "A senior security interest in the company's assets."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 6, "question": "What was the net loss for Esperion Therapeutics, Inc. for the year ended December 31, 2023?", "prediction": "According to the financial statements, Esperion Therapeutics, Inc. reported a net loss of $209.2 million for the year ended December 31, 2023.", "ground_truth": "$209.2 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 7, "question": "What were the net proceeds from the Registered Direct Offering for the year ended December 31, 2023?", "prediction": "According to the financial statements, the net proceeds to the Company from the Registered Direct Offering were approximately $51.3 million, after deducting placement agent fees and related offering expenses of $4.2 million.", "ground_truth": "Approximately $51.3 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 8, "question": "What was the net cash provided by investing activities for the year ended December 31, 2023?", "prediction": "According to the Statement of Cash Flows, net cash provided by investing activities for the year ended December 31, 2023 was $42.5 million.", "ground_truth": "$42,500 thousand."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 9, "question": "What is the effective annual imputed interest rate on the revenue interest liability as of December 31, 2023?", "prediction": "According to Note 10 in the financial statements, the effective annual imputed interest rate on the revenue interest liability is 17.6% as of December 31, 2023.", "ground_truth": "17.6%."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 1, "question": "What percentage of the company's revenue for the year ended December 31, 2023, came from its insurance verticals?", "prediction": "According to the financial statements, 96.6% of MediaAlpha's total revenue for the year ended December 31, 2023 came from its insurance verticals (property & casualty insurance, health insurance, and life insurance).", "ground_truth": "96.6% of the revenue."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 2, "question": "What was the aggregate principal amount outstanding under the 2021 Term Loan Facility as of December 31, 2023?", "prediction": "According to the financial statements, the aggregate principal amount outstanding under the 2021 Term Loan Facility was $171.0 million as of December 31, 2023.", "ground_truth": "$171.0 million."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 3, "question": "Which cloud infrastructure provider does the company rely on for hosting its platform?", "prediction": "According to the filing, MediaAlpha relies on Amazon Web Services (AWS) to deliver its platform to partners and host its platform, website, serve users, support operations, and host many internal tools used to operate the business.", "ground_truth": "The company relies on Amazon Web Services (AWS) for hosting its platform."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 4, "question": "What were the low and high closing sales prices of Class A common stock from the IPO through December 31, 2023?", "prediction": "According to the filing, the low and high closing sales prices of MediaAlpha's Class A common stock ranged from $5.36 to $64.11 per share, respectively, from the IPO in October 2020 through December 31, 2023.", "ground_truth": "The low and high closing sales prices of Class A common stock ranged from $5.36 to $64.11 per share."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 5, "question": "What was the revenue generated by the company for the year ended December 31, 2023?", "prediction": "According to the financial statements, MediaAlpha generated revenue of $388.1 million for the year ended December 31, 2023.", "ground_truth": "$388.1 million."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 6, "question": "What was the total Transaction Value for the year ended December 31, 2023?", "prediction": "For the year ended December 31, 2023, the total Transaction Value was $593.4 million.", "ground_truth": "$593,438 thousand."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 7, "question": "What is the total amount of goodwill reported as of December 31, 2023?", "prediction": "According to the financial statements, the total amount of goodwill reported as of December 31, 2023 was $47,739,000.", "ground_truth": "$47,739."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 8, "question": "What was the total revenue for MediaAlpha, Inc. for the year ended December 31, 2023?", "prediction": "MediaAlpha, Inc.'s total revenue for the year ended December 31, 2023 was $388.1 million.", "ground_truth": "$388,149,000."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 9, "question": "What was the balance of operating lease liabilities classified as non-current as of December 31, 2023?", "prediction": "According to the consolidated balance sheet, the operating lease liabilities classified as non-current (shown as \"Operating Lease Liabilities - Non-current\" under \"Other long-term liabilities\") was $1,650 thousand ($1.65 million) as of December 31, 2023.", "ground_truth": "$1,650 thousand."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 0, "question": "What is the primary endpoint that the Phase 2b clinical trial of MM120 met for the treatment of generalized anxiety disorder?", "prediction": "According to the text, the Phase 2b clinical trial of MM120 met its primary endpoint by demonstrating statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety (HAM-A) rating scale compared to placebo at Week 4. Specifically, MM120 100 µg showed a 7.6-point reduction compared to placebo at Week 4 (-21.3 MM120 vs. -13.7 placebo; p<0.0004; Cohen's d=0.88).", "ground_truth": "Statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety (HAM-A) rating scale compared to placebo at Week 4."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 1, "question": "When did the company enter into a collaboration with Dr. Matthias Liechti's lab at UHB?", "prediction": "According to the text, the company entered into a multi-year, exclusive collaboration with Dr. Matthias Liechti's lab at University Hospital Basel (UHB) on April 1, 2020.", "ground_truth": "On April 1, 2020."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 2, "question": "What does the Pediatric Research Equity Act require certain NDAs to contain?", "prediction": "According to the text, the Pediatric Research Equity Act requires certain NDAs or supplements to an NDA to contain data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective.", "ground_truth": "Data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 3, "question": "What is the maximum timeframe for the evaluation of a marketing authorization application in the EU?", "prediction": "According to the text, the maximum timeframe for the evaluation of a marketing authorization application in the EU is 210 days, not including clock stops during which applicants respond to questions from the competent authority.", "ground_truth": "The maximum timeframe is 210 days, not including clock stops during which applicants respond to questions from the competent authority."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 4, "question": "As of December 31, 2023, how much cash and cash equivalents did the company have?", "prediction": "As of December 31, 2023, the company had $99.7 million in cash and cash equivalents.", "ground_truth": "$99.7 million."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 5, "question": "What was the amount available for issuance under the shelf registration statement at December 31, 2023?", "prediction": "According to the text, at December 31, 2023, $99.8 million remained available for issuance under the shelf registration statement, of which $59.8 million was reserved for sales under the ATM (at-the-market equity offering program).", "ground_truth": "$99.8 million."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 6, "question": "What may cause material adverse changes in the final clinical trial data?", "prediction": "Based on the document, material adverse changes in final clinical trial data compared to interim/preliminary data can be caused by several factors:\n\n1. Changes as more patient data becomes available\n2. Results from ongoing patient enrollment\n3. Changes after completion of final patient evaluations\n4. Results of audit and verification procedures conducted on the trial data\n5. Changes in statistical analyses as full dataset is analyzed\n\nThe document notes that this is why interim/preliminary data should be viewed with caution until final trial results are available, as adverse changes in final data could significantly harm business prospects.", "ground_truth": "Material adverse changes in the final data compared to the interim data could significantly harm our business prospects."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 7, "question": "What impact does the failure to gain market access and acceptance of product candidates have on the company's revenue?", "prediction": "According to the text, if the company's product candidates fail to gain market access and acceptance, this will have a material adverse impact on their ability to generate revenue. Specifically, even if some product candidates achieve market access and acceptance, if the market proves not to be large enough, the company may not be able to generate significant revenue. This indicates that market access and acceptance are critical factors for the company's revenue generation potential.", "ground_truth": "It will have a material adverse impact on the ability to generate revenue to provide a satisfactory, or any, return on investments."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 8, "question": "What happens if the pricing of our product candidates is set at unsatisfactory levels or if reimbursement is unavailable or limited?", "prediction": "According to the document, if pricing of product candidates is set at unsatisfactory levels or if reimbursement is unavailable/limited, these outcomes could occur:\n\n1. Decreased or limited commercial uptake of the products\n2. Negative impact on ability to generate revenue \n3. The company may not be able to successfully commercialize the product candidates\n4. Sales and profit potential would be harmed\n5. Overall business and profitability would be adversely affected\n\nThis is a significant risk factor because pricing and reimbursement by government agencies and private payors is critical for commercial success of pharmaceutical products.", "ground_truth": "Our revenue from sales and the potential profitability of our product candidates in those countries would be negatively affected."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 9, "question": "As of December 31, 2023, how many full-time and part-time employees did the company have?", "prediction": "As of December 31, 2023, the company had 57 full-time and part-time employees, consisting of 36 in research and development and 21 in general and administrative.", "ground_truth": "57 full-time and part-time employees."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 0, "question": "How many business segments does NVIDIA Corporation report its business results in?", "prediction": "NVIDIA reports its business results in two segments: \"Compute & Networking\" and \"Graphics\".", "ground_truth": "NVIDIA Corporation reports its business results in two segments."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 1, "question": "As of the end of fiscal year 2024, how many employees were engaged in research and development at NVIDIA?", "prediction": "According to the report, as of the end of fiscal year 2024, NVIDIA had 22,200 employees engaged in research and development.", "ground_truth": "22,200 employees were engaged in research and development."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 2, "question": "What percentage of NVIDIA's revenue in fiscal year 2024 was generated from sales outside of the United States?", "prediction": "According to the report, 56% of NVIDIA's total revenue in fiscal year 2024 was generated from sales outside of the United States.", "ground_truth": "56% of NVIDIA's revenue was generated from sales outside of the United States in fiscal year 2024."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 3, "question": "How many employees are in the region impacted by the geopolitical conflict in and around Israel?", "prediction": "According to the report, NVIDIA has approximately 3,700 employees in Israel who primarily support the research and development, operations, and sales and marketing of their networking products.", "ground_truth": "There are approximately 3,700 employees in the region."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 4, "question": "What is the symbol under which NVIDIA's common stock is traded?", "prediction": "NVIDIA's common stock is traded on the Nasdaq Global Select Market under the symbol NVDA.", "ground_truth": "NVIDIA's common stock is traded under the symbol NVDA."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 5, "question": "What was NVIDIA's total revenue for fiscal year 2024?", "prediction": "NVIDIA's total revenue for fiscal year 2024 was $60.922 billion.", "ground_truth": "$60.9 billion."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 6, "question": "What was the amount of acquisition termination cost related to the Arm transaction recorded in fiscal year 2023?", "prediction": "NVIDIA recorded an acquisition termination cost of $1.4 billion in fiscal year 2023", "ground_truth": "$1.4 billion."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 7, "question": "What was the total shareholders' equity of NVIDIA Corporation as of January 28, 2024?", "prediction": "According to the Consolidated Balance Sheets, NVIDIA Corporation's total shareholders' equity as of January 28, 2024 was $42,978 million ($42.978 billion).", "ground_truth": "$42,978 million."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 8, "question": "What is the expected weighted average period over which the unearned stock-based compensation expense will be recognized for RSUs, PSUs, and market-based PSUs as of January 28, 2024?", "prediction": "According to Note 4 of the financial statements, the weighted average period over which the unearned stock-based compensation expense will be recognized is 2.5 years for RSUs, PSUs, and market-based PSUs as of January 28, 2024.", "ground_truth": "2.5 years."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 9, "question": "What was NVIDIA's total revenue for the year ended January 28, 2024?", "prediction": "NVIDIA's total revenue for the year ended January 28, 2024 was $60.922 billion.", "ground_truth": "$60,922 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 0, "question": "What is the page number for the 'Signature' section in this financial statement?", "prediction": "The Signature section begins on page 150 of the financial statement.", "ground_truth": "150"}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 1, "question": "What is the expected expiration year of U.S. Patent No. 9,265,740 related to omadacycline?", "prediction": "According to the text, U.S. Patent No. 9,265,740 (a method of use patent for omadacycline) is expected to be extended until October 2030.", "ground_truth": "The method of use patent (U.S. 9,265,740) is expected to be extended until October 2030."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 2, "question": "What is the primary business segment for Paratek Pharmaceuticals, Inc. as defined by generally accepted accounting principles?", "prediction": "According to the financial statements, Paratek Pharmaceuticals, Inc. operates its business as a single segment only.\n\nThe relevant quote from the 10-K states: \"We operate our business as a single segment, as defined by generally accepted accounting principles.\"", "ground_truth": "Paratek Pharmaceuticals, Inc. operates its business as a single segment."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 3, "question": "What is the withdrawal quantity of NUZYRA's second procurement accepted by BARDA in December 2022?", "prediction": "According to the financial statements, BARDA's second procurement of NUZYRA was for 2,500 treatment courses at a value of $36.4 million, which was delivered to and accepted by BARDA in December 2022.", "ground_truth": "2,500 treatment courses of NUZYRA."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 4, "question": "What is the annual interest rate for the 4.75% Convertible Senior Subordinated Notes issued in April 2018?", "prediction": "The Notes bear cash interest at an annual rate of 4.75%, payable on November 1 and May 1 of each year.", "ground_truth": "The Notes bear cash interest at the annual rate of 4.75%."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 5, "question": "What was the net loss for the year ended December 31, 2022?", "prediction": "The net loss for the year ended December 31, 2022 was $63,566,000 (or $63.6 million).", "ground_truth": "$63.6 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 6, "question": "What was the net loss for Paratek Pharmaceuticals, Inc. for the year ended December 31, 2022?", "prediction": "According to the financial statements, Paratek Pharmaceuticals, Inc.'s net loss for the year ended December 31, 2022 was $63.6 million.", "ground_truth": "$63.6 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 7, "question": "What was Paratek Pharmaceuticals, Inc.'s accumulated deficit through December 31, 2022?", "prediction": "According to the financial statements, Paratek Pharmaceuticals, Inc.'s accumulated deficit through December 31, 2022 was $930.4 million.", "ground_truth": "$930.4 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 8, "question": "What was the Company's total cash, cash equivalents and restricted cash as of December 31, 2022?", "prediction": "As of December 31, 2022, the Company's total cash, cash equivalents and restricted cash was $34.4 million (specifically $34,373,000), as shown in the Consolidated Statement of Cash Flows.", "ground_truth": "$34.4 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 9, "question": "What was the total coupon interest expense recognized by the Company for the R-Bridge Loan Agreement in the year ended December 31, 2022?", "prediction": "According to the financial statements, the Company recognized coupon interest expense of $4.4 million on the R-Bridge Loan Agreement for the year ended December 31, 2022.", "ground_truth": "$4.4 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 0, "question": "Which two reportable segments does Tesla, Inc. operate?", "prediction": "According to the filing, Tesla operates two reportable segments:\n\n1. Automotive\n2. Energy generation and storage", "ground_truth": "Automotive and energy generation and storage."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 1, "question": "As of December 31, 2023, what was Tesla's worldwide employee headcount?", "prediction": "According to the report, Tesla's worldwide employee headcount was 140,473 as of December 31, 2023.", "ground_truth": "140,473."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 2, "question": "As of December 31, 2023, how much aggregate principal amount of indebtedness did Tesla and its subsidiaries have outstanding?", "prediction": "According to the financial statements, as of December 31, 2023, Tesla and its subsidiaries had outstanding $4.68 billion in aggregate principal amount of indebtedness.", "ground_truth": "$4.68 billion."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 3, "question": "What was the intra-day trading high and low of the company's common stock over the last 52 weeks?", "prediction": "According to the document, Tesla's common stock had an intra-day trading high of $299.29 per share and a low of $152.37 per share over the last 52 weeks.", "ground_truth": "The intra-day trading high was $299.29 per share and the low was $152.37 per share."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 4, "question": "What was the automotive sales revenue for the year ended December 31, 2023?", "prediction": "According to the financial statements, Tesla's automotive sales revenue for the year ended December 31, 2023 was $78,509 million ($78.509 billion).", "ground_truth": "$78,509 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 5, "question": "What was Tesla, Inc.'s total revenue for the year ended December 31, 2023?", "prediction": "Tesla's total revenue for the year ended December 31, 2023 was $96.773 billion.", "ground_truth": "$96,773 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 6, "question": "What was the total cash and cash equivalents and restricted cash as of December 31, 2023?", "prediction": "According to the consolidated statements of cash flows, Tesla's total cash and cash equivalents and restricted cash as of December 31, 2023 was $17,189 million.", "ground_truth": "$17,189 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 7, "question": "What was the carrying value of digital assets, net, as of December 31, 2023?", "prediction": "According to the consolidated balance sheet, Tesla's digital assets, net, had a carrying value of $184 million as of December 31, 2023.", "ground_truth": "$184 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 8, "question": "What was Tesla's total revenue for the year ended December 31, 2023?", "prediction": "Tesla's total revenue for the year ended December 31, 2023 was $96.773 billion.", "ground_truth": "$96,773 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 9, "question": "Which independent registered public accounting firm audited the effectiveness of internal control over financial reporting as of December 31, 2023?", "prediction": "PricewaterhouseCoopers LLP (PCAOB ID: 238) audited the effectiveness of Tesla's internal control over financial reporting as of December 31, 2023.", "ground_truth": "PricewaterhouseCoopers LLP."}
